Point72 Asia (Singapore)’s Blueprint Medicines BPMC Stock Holding History

Point72 Asia (Singapore)’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,365	Closed	-$7.1M	–	926
2025 Q2	$7.1M	Buy	+55,365	New	+$5.75M	1.26%	12
2025 Q1	–	Sell	-1,220	Closed	-$106K	–	894
2024 Q4	$106K	Buy	+1,220	New	+$112K	0.03%	354

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Point72 Asia (Singapore)'s BPMC Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 55,365 shares — an estimated $7.1M sold.

Point72 Asia (Singapore) first reported a position in BPMC in Q4 2024 and held it in 2 quarters. The position peaked at $7.1M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Point72 Asia (Singapore) reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Point72 Asia (Singapore) sold 55,365 Blueprint Medicines shares in Q3 2025, an estimated $7.1M.
Point72 Asia (Singapore) first reported a position in Blueprint Medicines in Q4 2024 and held it in 2 quarters.
Point72 Asia (Singapore)'s Blueprint Medicines position peaked at $7.1M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.